| Patents for C07K 7 - Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof (42,273) |
|---|
| 10/11/2001 | CA2403242A1 Binding peptides for carcinoembryonic antigen (cea) |
| 10/11/2001 | CA2402416A1 Selective linear peptides with melanocortin-4 receptor (mc4-r) agonist activity |
| 10/10/2001 | EP1143000A1 Screening method |
| 10/10/2001 | EP1141375A1 Metallopeptide combinatorial libraries and applications |
| 10/10/2001 | EP1141250A2 Intein-mediated cyclization of peptides |
| 10/10/2001 | EP1140995A2 Peptides for inhibiting hbv core proteins |
| 10/10/2001 | EP1140993A1 Glycopeptide derivatives and pharmaceutical compositions containing the same |
| 10/10/2001 | EP1140992A1 Cyclic peptide antifungal agents having a sugar substituent |
| 10/10/2001 | EP1140991A1 Cyclic peptide antifungal agents |
| 10/10/2001 | EP1140990A1 Penicillins as pharmaceuticals for the downregulation of ifn gamma production |
| 10/10/2001 | EP1140989A1 Alpha(v) beta(6) integrin inhibitors |
| 10/10/2001 | EP1140988A1 Halovir, an antiviral marine natural product, and derivatives thereof |
| 10/10/2001 | EP1140987A1 Peptides for inhibiting hpv e6 proteins |
| 10/10/2001 | EP1140986A1 Pseudopeptide, synthesis method, reagent and applications |
| 10/10/2001 | EP1140864A2 Vitronectin receptor antagonist pharmaceuticals |
| 10/10/2001 | EP1140202A1 Peptidic product, process and composition |
| 10/10/2001 | EP1140133A1 Controlled release formulation comprising gnrh-ii |
| 10/10/2001 | EP1140130A2 Inhibition of angiogenesis by high molecular weight kininogen domain 3 peptide analogs |
| 10/10/2001 | EP0830372B1 Cyclic prodrugs of peptides and peptide nucleic acids having improved metabolic stability and cell membrane permeability |
| 10/10/2001 | CN1317088A Diagnostic method for detecting disturbances of pancreas |
| 10/10/2001 | CN1317011A Process for couping amino acids using bis-(trichloromethyl) carbonate |
| 10/09/2001 | US6300471 FSH-releasing peptides |
| 10/09/2001 | US6300317 Eukarotic cells, polynucleotide, functional agents, membrane permeability, subcellar localization agents and polynucleotide masking agents |
| 10/09/2001 | US6300088 The detection of an activated peptide, that is cleaved from the prostate specific antigen during activation, for cancer diagnosis; the a biological sample is obtained and the peptide is detected in the sample by immunoassay |
| 10/09/2001 | US6300079 Polypeptide and process for measuring living body components using the same |
| 10/04/2001 | WO2001072958A2 Bladder cancer-specific peptides for diagnosis and therapy |
| 10/04/2001 | WO2001072956A2 Compounds and methods for modulating desmosomal cadherin-mediated functions |
| 10/04/2001 | WO2001072846A2 Ligands directed to the non-secretory component, non-stalk region of pigr and methods of use thereof |
| 10/04/2001 | WO2001072831A2 Immunoregulator |
| 10/04/2001 | WO2001072829A2 Peptides blocking vascular endothelial growth factor (vegf)-mediated angiogenesis, polynucleotides encoding said peptides and methods of use thereof |
| 10/04/2001 | WO2001072782A2 Immuno-reactive peptide ctl epitopes of human cytomegalovirus |
| 10/04/2001 | WO2001072771A2 Insulin and igf-1 receptor agonists and antagonists |
| 10/04/2001 | WO2001072770A1 Insulin potentiating peptides |
| 10/04/2001 | WO2001072277A2 Immunotherapeutic methods and compositions |
| 10/04/2001 | WO2001013957A3 Enhancing drug delivery across and into epithelial tissues using oligo arginine moieties |
| 10/04/2001 | US20010027247 Autoimmune diseases; inflammatory conditions; competitive binding with Human Leukocyte Antigen displacing disease-inducing endogenous peptides |
| 10/04/2001 | US20010027174 Polypeptides containing neo-tryptophan; neurotensin analogs; neotryptophan derivatives; method of synthesis starting from 2-methyl-3-nitrobenzoic acid; administering to a mammal having a serotonin recognition molecule |
| 10/04/2001 | EP1138692A1 Fragments of human chorionic gonadotropin (hcg) as immunoregulator |
| 10/04/2001 | EP1137763A1 Glucoamylases with n-terminal extensions |
| 10/04/2001 | EP1137664A2 Protein transduction system and methods of use thereof |
| 10/04/2001 | EP1137663A2 Purification of echinocandin cyclopeptide compounds |
| 10/04/2001 | EP1137659A1 Inhibition of angiogenesis by high molecular weight kininogen and peptide analogs thereof |
| 10/04/2001 | EP1137631A1 REVERSIBLE AQUEOUS pH SENSITIVE LIPIDIZING REAGENTS, COMPOSITIONS AND METHODS OF USE |
| 10/04/2001 | EP0973800A4 Novel receptor |
| 10/04/2001 | EP0835309B1 Vaccine for infectious agents, composition for treating and preventing hiv infections |
| 10/04/2001 | EP0815123B1 Beta-sheet mimetics and use thereof as protease inhibitors |
| 10/04/2001 | EP0688314B1 Prodrug derivatives of enzyme inhibitors with hydroxyl groups, methods of preparing them and their use |
| 10/04/2001 | EP0606463B1 Neuromedin b receptor antagonists |
| 10/04/2001 | CA2404756A1 Ligands directed to the non-secretory component, non-stalk region of pigr and methods of use thereof |
| 10/04/2001 | CA2404528A1 Peptides blocking vascular endothelial growth factor (vegf)-mediated angiogenesis, polynucleotides encoding said peptides and methods of use thereof |
| 10/04/2001 | CA2404202A1 Compounds and methods for modulating desmosomal cadherin-mediated functions |
| 10/04/2001 | CA2402780A1 Insulin and igf-1 receptor agonists and antagonists |
| 10/04/2001 | CA2401638A1 Immuno-reactive peptide ctl epitopes of human cytomegalovirus |
| 10/03/2001 | CN1315965A Hepatitis C inhibitor peptides |
| 10/03/2001 | CN1315961A Glycopeptide derivatives and pharmaceutical compositions containing same |
| 10/03/2001 | CN1315869A Artificial T helper cell epitopes as immune stimulators for synthetic peptide immunogens including immunogenic LHRH peptides |
| 10/02/2001 | US6297354 Useful in treatment of disease conditions which are mediated by reproductive hormones, including benign prostate hyperplasia, prostate tumors, breast and ovaries tumors, cryptorchidism, hirsuitism, gastric motility disorders |
| 10/02/2001 | US6297215 Microbiocides for treatment of endotoxemia or sepsis by administering |
| 10/02/2001 | US6297213 Osteogenic devices |
| 10/02/2001 | US6297050 Activation of t-cell response; mix peptides with sample containing t-cells and detect bound human leukocyte antigens |
| 10/02/2001 | US6297041 MN gene and protein |
| 10/02/2001 | US6297026 Nucleic acids encoding the C140 receptor |
| 10/02/2001 | US6297018 Locating sample at examination site, illuminating with polarized light, detecting light emitted only from volume located away from sample boundary interfaces, then analyzing data |
| 10/02/2001 | CA2086243C Anticoagulant peptides |
| 10/02/2001 | CA2078000C Neutrophil stimulating peptides |
| 10/02/2001 | CA2041268C Peptides with a bradykinin-antagonistic action |
| 10/02/2001 | CA2035917C Stabilized sulfonate, sulfate, phosphonate and phosphate derivatives of hirudin |
| 09/27/2001 | WO2001071358A1 Method of screening for inhibitors of osteopontin |
| 09/27/2001 | WO2001071346A2 Binding compounds for cc chemokine receptor 5 and methods for identifying them |
| 09/27/2001 | WO2001070930A2 Growth factor binding molecules |
| 09/27/2001 | WO2001070772A2 Molecule of pharmaceutical interest comprising at its n-terminal a glutamic acid or a glutamine in the form of an addition salt to an acid |
| 09/27/2001 | WO2001070769A1 Peptide derivative |
| 09/27/2001 | WO2001070768A2 Receptor-binding compounds and method for identifying them |
| 09/27/2001 | WO2001070767A2 Therapeutic anti-melanoma compounds |
| 09/27/2001 | WO2001070766A2 Therapeutic anti-cytomegalovirus compounds |
| 09/27/2001 | WO2001070765A1 Receptor-binding compounds and methods for identifying them |
| 09/27/2001 | WO2001070672A2 Compounds and methods to treat alzheimer's disease |
| 09/27/2001 | US20010025035 Water soluble prodrugs of hindered alcohols |
| 09/27/2001 | US20010025025 Reacting cyclosporin with hexamethyldisilazane in prevence of a metal halide |
| 09/27/2001 | DE10012120A1 New ligand, comprising therapeutic or diagnostic agent bonded non-covalently with substance having high affinity to transport molecule |
| 09/27/2001 | CA2404139A1 Binding compounds and methods for identifying binding compounds |
| 09/27/2001 | CA2403803A1 Molecule of pharmaceutical interest comprising at its n-terminal a glutamic acid or a glutamine in the form of a physiologically acceptable strong acid |
| 09/27/2001 | CA2403788A1 Receptor-binding compounds and methods for identifying them |
| 09/27/2001 | CA2403784A1 Binding compounds and methods for identifying binding compounds |
| 09/27/2001 | CA2403684A1 Therapeutic anti-melanoma compounds |
| 09/27/2001 | CA2403681A1 Therapeutic anti-cytomegalovirus compounds |
| 09/27/2001 | CA2403447A1 Peptide derivative |
| 09/27/2001 | CA2401749A1 Compounds and methods to treat alzheimer's disease |
| 09/26/2001 | EP1136500A2 Seroreactive regions from the HPV proteins E1 and E2 |
| 09/26/2001 | EP1136498A1 Inhibitors of serine proteases, particularly hepatitis c virus NS3 protease |
| 09/26/2001 | EP1135509A2 Chlamydia antigens and corresponding dna fragments and uses thereof |
| 09/26/2001 | EP1135475A1 Human plasminogen activator |
| 09/26/2001 | EP1135410A2 Antennapedia homeodomain helix 3 derived translocation vectors |
| 09/26/2001 | EP1135169A1 Pharmaceutical composition comprising an anti-cancer agent and at least a peptide |
| 09/26/2001 | EP1135159A2 Peptide-based vaccine for influenza |
| 09/26/2001 | EP0842142B1 Process for producing alpha-(n,n dialkyl)-amino carboxylic acid amides |
| 09/26/2001 | EP0809653B1 Helicobacter pylori antigen |
| 09/26/2001 | EP0805685B1 Novel antifungal cyclohexapeptides |
| 09/26/2001 | EP0702558B1 Novel opioid peptide inhibitors |
| 09/26/2001 | EP0683792B1 Lhrh antagonists having modified aminoacyl residues at postions 5 and 6 |